In a separate but coordinated project funded by other Korean donors, IVI and Ethiopian partners will immunize an additional 60,000 people against the diarrheal disease in Ethopia. IVI and partners will provide two doses of oral cholera vaccine (OCV) to around 100,000 residents at risk of the water-borne diarrheal disease in Shashemene Town and Woreda in the Oromia region during the month of May, and establish a disease monitoring system to strengthen local public health capabilities in Ethiopia. The mass vaccination campaign will use Euvichol-Plus, the OCV developed by IVI and produced by the Korean vaccine manufacturer EuBiologics. The vaccine, which was prequalified by the WHO in 2017, has been proven to be safe and effective and is widely used in cholera control efforts worldwide. In the ECCP-KSC project, IVI will vaccinate an additional 60,000 people in the same region in Ethiopia, conduct follow-up studies for at least two years to measure vaccine impact and implement disease surveillance.

Source: Ethiopian News May 13, 2022 21:41 UTC